{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=16", "query": { "condition": "Gene Expression", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 785, "total_pages": 79, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gene+Expression&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T21:05:15.836Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01372995", "title": "Vitamin D in Ventilated ICU Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Failure" ], "interventions": [ { "name": "Enteral Vitamin D3 50,000 IU", "type": "DRUG" }, { "name": "Enteral Vitamin D3 100,000IU", "type": "DRUG" }, { "name": "Inactive substance", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2011-07", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-01-09", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01372995" }, { "nct_id": "NCT05245071", "title": "Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tusamitamab ravtansine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-06-01", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 2, "location_summary": "Buffalo, New York • El Paso, Texas", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05245071" }, { "nct_id": "NCT05984953", "title": "Rosuvastatin and Evolocumab for Coronary Artery Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "statin", "type": "DRUG" }, { "name": "evolocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2013-08-01", "completion_date": "2022-10-28", "has_results": false, "last_update_posted_date": "2023-08-09", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05984953" }, { "nct_id": "NCT01501929", "title": "Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Metoprolol succinate", "type": "DRUG" }, { "name": "Nebivolol", "type": "DRUG" }, { "name": "Non-invasive measurement of Cardiac Output (CO)", "type": "PROCEDURE" }, { "name": "Endothelial cell collection", "type": "PROCEDURE" }, { "name": "Microvascular perfusion assessment using Definity", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2010-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-11-06", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01501929" }, { "nct_id": "NCT00009581", "title": "Nitric Oxide to Improve Blood Flow in Sickle Cell Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Anemia" ], "interventions": [ { "name": "L-NMMA", "type": "DRUG" }, { "name": "Acetylcholine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 65, "start_date": "2001-01", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009581" }, { "nct_id": "NCT07054866", "title": "Rural Autistic Individuals - Supporting Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Autism Disorder", "Language Development Disorders", "ADHD", "Typical Development", "Rural Health", "Children", "Neuroimaging", "Eye Tracking", "EEG", "fNIRS" ], "interventions": [ { "name": "Speech-Gesture combinations", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Montana State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 50, "start_date": "2025-10-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "Bozeman, Montana", "locations": [ { "city": "Bozeman", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07054866" }, { "nct_id": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "T-DXd", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Volrustomig", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2021-03-09", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 13, "location_summary": "Duarte, California • Newport Beach, California • Orange, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04686305" }, { "nct_id": "NCT00718172", "title": "Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Liver Biopsy", "type": "PROCEDURE" }, { "name": "Peginterferon & Ribavirin for Hepatitis C", "type": "DRUG" }, { "name": "Pre-treatment Ribavirin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2008-07-11", "completion_date": "2014-08-19", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00718172" }, { "nct_id": "NCT00196001", "title": "Adrenocorticotropic Hormone (ACTH) Stimulation and G Protein", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adrenal Sufficiency" ], "interventions": [], "intervention_types": [], "sponsor": "Children's Mercy Hospital Kansas City", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "6 Years to 60 Years" }, "enrollment_count": 35, "start_date": "2005-07", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2021-01-13", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00196001" }, { "nct_id": "NCT00720993", "title": "Colorectal Cancer Screening Validation Study", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer Screening" ], "interventions": [], "intervention_types": [], "sponsor": "IntelliGeneScan, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 165, "start_date": "2008-08", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2009-04-23", "last_synced_at": "2026-11-11T21:05:15.836Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720993" } ] }